Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VGX-6150 · 1 trial · 1 indication
To evaluate the safety and tolerability of VGX-6150 as second-line therapy in chronic hepatitis C patients.
| Arm | Type | Description |
|---|---|---|
| Experimental: 1mg of DNA/dose | EXPERIMENTAL | Subjects will receive a 3 dose series of VGX-6150 containing 1mg DNA/dose administered via IM injection + electroporation at Day 0, Week 4, Week 8, Week 12 |
| Experimental: 3mg of DNA/dose | EXPERIMENTAL | Subjects will receive a 3 dose series of VGX-6150 containing 3mg DNA/dose administered via IM injection + electroporation at Day 0, Week 4, Week 8, Week 12 |
| Experimental: 6mg of DNA/dose | EXPERIMENTAL | Subjects will receive a 3 dose series of VGX-6150 containing 6mg DNA/dose administered via IM injection + electroporation at Day 0, Week 4, Week 8, Week 12 |
| Name | Type | Description |
|---|---|---|
| VGX-6150 | BIOLOGICAL | Plasmid DNA delivered via IM injection with electroporation |
Inclusion Criteria: * Subjects who want to participate in this trial should meet all of the following criteria. 1. Male or females aged 19 to 65 years 2. Chronic hepatitis C patients infected with HCV genotype 1a or 1b 3. Patients who failed\* SOC therapy with PEG-IFN and ribavirin or triple...
VGX-6150 is an investigational monoclonal antibody developed by Inovio Pharmaceuticals, Inc. for chronic Hepatitis C infection. It was studied as a second-line therapy for patients with chronic Hepatitis C. The candidate has completed a single Phase 1 clinical trial and remains in clinical development.
VGX-6150 was developed for second-line therapy of chronic Hepatitis C infection, meaning treatment of patients who had already received prior therapy. It is an investigational monoclonal antibody and is not an approved treatment. Its only clinical study enrolled 18 patients with chronic Hepatitis C in South Korea.
VGX-6150 is developed by Inovio Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker INO. Inovio is the sponsor of the clinical program evaluating the monoclonal antibody in chronic Hepatitis C infection.
VGX-6150 is in Phase 1 development. Its single clinical trial, a Phase 1 study in chronic Hepatitis C, has been completed, and no active trials are currently listed. The drug is investigational and has not been approved for any indication.
VGX-6150 has been studied in one clinical trial, NCT02027116, titled a Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection. The trial was completed, enrolled 18 participants, and was conducted in South Korea.